Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in J Infect Dis Retrieve available abstracts of 44 articles: HTML format

Single Articles

March 2023
1. SUEHIRO Y, Tsuge M, Kurihara M, Uchida T, et al
   Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL.
   J Infect Dis. 2023;227:686-695.
   PubMed     Abstract available
   
   
   February 2023
2. SACHITHANANDHAM J, Balagopal A, Leep-Lazar J, Quinn J, et al
   Second-phase hepatitis C plasma viral kinetics directly reflects reduced intrahepatic burden of HCV.
   J Infect Dis. 2023 Feb 1:jiad025. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2023
3. THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
   Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
   J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
   PubMed    
   
   
   December 2022
4. YU T, Zhang M, Zhang H, Zheng J, et al
   Evidence of Residual Ongoing Viral Replication in Chronic Hepatitis B Patients Successfully Treated with Nucleos(t)ide Analogues.
   J Infect Dis. 2022 Dec 22:jiac493. doi: 10.1093.
   PubMed     Abstract available
   
   
   November 2022
5. LIND ML, Copin R, McCarthy S, Coppi A, et al
   Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
   J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
   PubMed     Abstract available
   
   
   October 2022
6. MILLER-ARCHIE SA, Walters SC, Bocour A, Moore MS, et al
   The Impact of Supportive Housing on Liver-Related Outcomes Among Persons With Hepatitis C Virus Infection.
   J Infect Dis. 2022;226.
   PubMed     Abstract available
   
   
   September 2022
7. HALL SA, Burns GS, Mooney BJ, Millen R, et al
   Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
   J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
   PubMed     Abstract available
   
   
   August 2022
8. VETTER BN, Reipold EI, Ongarello S, Audu R, et al
   Sensitivity and Specificity of Rapid Diagnostic Tests for Hepatitis C Virus With or Without HIV Coinfection: A Multicentre Laboratory Evaluation Study.
   J Infect Dis. 2022;226:420-430.
   PubMed     Abstract available
   
   
   
9. OGAWA E, Nomura H, Nakamuta M, Furusyo N, et al
   Development of Hepatocellular Carcinoma in Patients Aged 75-84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals.
   J Infect Dis. 2022;226:431-440.
   PubMed     Abstract available
   
   
   
10. KITABAYASHI J, Shirasaki T, Shimakami T, Nishiyama T, et al
    Upregulation of the Long Noncoding RNA HULC by Hepatitis C Virus and Its Regulation of Viral Replication.
    J Infect Dis. 2022;226:407-419.
    PubMed     Abstract available
    
    
    
11. GARDNER AR, Ma Y, Bacchetti P, Price JC, et al
    Longitudinal Assessment of the Enhanced Liver Fibrosis Score in the Era of Contemporary HIV and Hepatitis C Virus Treatment.
    J Infect Dis. 2022 Aug 11. pii: 6650396. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2022
12. PEREZ-GARCIA F, Vazquez-Moron S, Burgueno-Garcia I, Jose Munoz-Gomez M, et al
    Hepatitis E virus seroprevalence is associated with neurodegenerative disorders in older people with dementia: a case-control study.
    J Infect Dis. 2022 Jun 27. pii: 6618639. doi: 10.1093.
    PubMed     Abstract available
    
    
    
13. SONNEVELD MJ, Hansen BE, Brouwer WP, Chan HL, et al
    Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study.
    J Infect Dis. 2022;225:1967-1973.
    PubMed     Abstract available
    
    
    May 2022
14. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    PubMed    
    
    
    
15. BRAKENHOFF SM, de Knegt RJ, Oliveira J, van der Eijk AA, et al
    Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients.
    J Infect Dis. 2022 May 23. pii: 6590452. doi: 10.1093.
    PubMed     Abstract available
    
    
    
16. MOHAREB AM, Liu AF, Kim AY, Coffie PA, et al
    Clearance of hepatitis B "e" antigen in untreated chronic HBV infection: a systematic review and meta-analysis.
    J Infect Dis. 2022 May 2. pii: 6576758. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2022
17. MONTANARI NR, Conceicao-Neto N, Van Den Wyngaert I, Van Oord GW, et al
    Differential gene expression, irrespective of circulating Hepatitis B Surface Antigen levels, between Inactive Carrier and Nucleos(t)ide Analogue-Treated Hepatitis B Virus patients.
    J Infect Dis. 2022;225:1471-1476.
    PubMed     Abstract available
    
    
    March 2022
18. RICO MONTANARI N, Ramirez R, Van Buuren N, van den Bosch TPP, et al
    Transcriptomic Analysis of Livers of Inactive Carriers of Hepatitis B Virus With Distinct Expression of Hepatitis B Surface Antigen.
    J Infect Dis. 2022;225:1081-1090.
    PubMed     Abstract available
    
    
    
19. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2022
20. CATLETT B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, et al
    Diagnostic accuracy of assays using point-of-care testing or dried blood spot samples for the determination of HCV RNA: a systematic review.
    J Infect Dis. 2022 Feb 12. pii: 6527696. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2022
21. SPRADLING PR, Xing J, Zhong Y, Rupp LB, et al
    Incidence of malignancies among patients with chronic hepatitis B in US health care organizations, 2006-2018.
    J Infect Dis. 2022 Jan 17. pii: 6510085. doi: 10.1093.
    PubMed     Abstract available
    
    
    
22. KHALFI P, Suspene R, Caval V, Thiers V, et al
    APOBEC3C S188I polymorphism enhances context specific editing of Hepatitis B virus genome.
    J Infect Dis. 2022 Jan 12. pii: 6504007. doi: 10.1093.
    PubMed     Abstract available
    
    
    December 2021
23. LIU S, Deng R, Zhou B, Liang X, et al
    Association of serum hepatitis B virus RNA with hepatocellular carcinoma risk in chronic hepatitis B patients under nucleos(t)ide analogues therapy.
    J Infect Dis. 2021 Dec 21. pii: 6472568. doi: 10.1093.
    PubMed     Abstract available
    
    
    
24. CHIEN-HUNG C, Peng CY, Kuo YH, Hu TH, et al
    Earlier and higher rate of hepatitis B virus relapse after discontinuing tenofovir versus entecavir in HBeAg-positive patients.
    J Infect Dis. 2021 Dec 11. pii: 6459556. doi: 10.1093.
    PubMed     Abstract available
    
    
    
25. COSTAFREDA MI, Sauleda S, Rico A, Piron M, et al
    Detection of non-enveloped hepatitis E virus in plasma of infected blood donors.
    J Infect Dis. 2021 Dec 4. pii: 6449510. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2021
26. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2021
27. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available
    
    
    
28. AZMAN AS, Paul KK, Bhuiyan TR, Koyuncu A, et al
    Hepatitis E in Bangladesh: Insights from a National Serosurvey.
    J Infect Dis. 2021 Sep 22. pii: 6373659. doi: 10.1093.
    PubMed     Abstract available
    
    
    
29. WARD KM, Falade-Nwulia O, Moon J, Sutcliffe CG, et al
    Non-adherence to LDV/SOF did not predict SVR in a randomized controlled trial of HIV/HCV coinfected persons who use drugs.
    J Infect Dis. 2021 Sep 20. pii: 6372878. doi: 10.1093.
    PubMed     Abstract available
    
    
    
30. RYDELL GE, Prakash K, Larsson SB, Skoglund C, et al
    Quantification of viral RNA in multiple pieces of explant liver tissue shows distinct focal differences of hepatitis B infection.
    J Infect Dis. 2021 Sep 17. pii: 6371942. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2021
31. CHANG KC, Chang MH, Chen HL, Wu JF, et al
    Universal Infant Hepatitis B Virus (HBV) Vaccination for 35 years: moving toward the Eradication of HBV.
    J Infect Dis. 2021 Aug 7. pii: 6345224. doi: 10.1093.
    PubMed     Abstract available
    
    
    July 2021
32. JOHNSON VALIENTE A, Liem KS, Schwarz KB, Rosenthal P, et al
    The Inflammatory Cytokine Profile Associated with Liver Damage is Broader and Stronger in Chronic Hepatitis B Patients Compared to Acute Hepatitis B Patients.
    J Infect Dis. 2021 Jul 21. pii: 6324833. doi: 10.1093.
    PubMed     Abstract available
    
    
    
33. SPRADLING PR, Xing J, Harris AM, Ly KN, et al
    Estimated prevalence and number of persons with isolated antibody to hepatitis B core antigen and associated occult hepatitis B, United States, 2001-2018.
    J Infect Dis. 2021 Jul 12. pii: 6319558. doi: 10.1093.
    PubMed     Abstract available
    
    
    
34. GU S, Wang W, Ye G, Chen C, et al
    Hepatocyte-derived L-carnitine restricts hepatitis B surface antigen loss through an immunosuppressive effect on germinal center-related immune cells.
    J Infect Dis. 2021 Jul 2. pii: 6313212. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2021
35. NDOW G, Cessay A, Cohen D, Shimakawa Y, et al
    Prevalence and clinical significance of occult hepatitis B infection in The Gambia, West Africa.
    J Infect Dis. 2021 Jun 23. pii: 6308183. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2021
36. HSU YC, Yeh ML, Wong GL, Chen CH, et al
    Incidences and Determinants of Functional Cure during Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B.
    J Infect Dis. 2021 May 17. pii: 6276897. doi: 10.1093.
    PubMed     Abstract available
    
    
    April 2021
37. GONZALEZ HC, Trudeau S, Gordon SC
    Editorial: Changing trends in the US prevalence of hepatitis B core antibody provide important perspectives into future screening and vaccination strategies.
    J Infect Dis. 2021 Apr 27. pii: 6254533. doi: 10.1093.
    PubMed    
    
    
    
38. LY KN, Xing J, Spradling PR
    Trends in Prevalence and Characteristics of Resolved and Current Hepatitis B among US-Born Persons: National Health and Nutrition Examination Survey, 2001-2018.
    J Infect Dis. 2021 Apr 27. pii: 6254685. doi: 10.1093.
    PubMed     Abstract available
    
    
    
39. YUAN W, Huang D, Wu D, Chen Y, et al
    Peg IFN-a Treatment Enhanced the Inhibitory Effect of NK Cells on the Differentiation and Proliferation of CD4 +CD25 + Tregs via IFN-gamma in Chronic Hepatitis B.
    J Infect Dis. 2021 Apr 19. pii: 6236316. doi: 10.1093.
    PubMed     Abstract available
    
    
    
40. LIU Z, Huang CJ, Huang YH, Pan MH, et al
    HLA zygosity increases risk of hepatitis B virus-associated hepatocellular carcinoma.
    J Infect Dis. 2021 Apr 14. pii: 6225842. doi: 10.1093.
    PubMed     Abstract available
    
    
    March 2021
41. ARANDAY-CORTES E, McClure CP, Davis C, Irving WL, et al
    Real-World Outcomes of DAA Treatment and Retreatment in UK-based Patients Infected with HCV Genotypes/Subtypes Endemic in Africa.
    J Infect Dis. 2021 Mar 1. pii: 6154708. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2021
42. WU W, Wu D, Yan W, Wang Y, et al
    Interferon-Induced Macrophage-Derived Exosomes Mediate Antiviral Activity Against Hepatitis B Virus Through miR-574-5p.
    J Infect Dis. 2021;223:686-698.
    PubMed     Abstract available
    
    
    October 2020
43. YOSHIKAWA S, Yoshio S, Yoshida Y, Tsutsui Y, et al
    Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.
    J Infect Dis. 2020 Oct 19. pii: 5929874. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2020
44. WU JF, Chang KC, Ni YH, Hsu HY, et al
    Impacts of the percentage of basal core promoter mutation on the progression of liver fibrosis after HBeAg-seroconversion.
    J Infect Dis. 2020 Aug 29. pii: 5899201. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: